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OBJECTIVES: To analyze use of anti-infective drugs for systemic administration
(ATC-group J) in Serbia in 2010 year. METHODS: Data about use of anti-infective
drugs for systemic administration in Serbia in 2010 was taken from the Agency for
Drugs and Medical Devices of Serbia. RESULTS: Total use of all drugs in Serbia in
2010 was 966,26 DDD/1000 inhabitants/day. ATC-group J was on the eighth place
according to amount of DDDs with 19,63 DDD/1000 inh/day or 2,03% of total con-
sumption. According to the funding spent, this group was on the second position
with 90.651.670,00€. In this group, subgroup with highest consumption were anti-
bacterial drugs for systemic use (subgroup J01), with 19,35 DDD/1000 inh/day or
98,57% of total use in group J. This subgroup takes first place in funding spent with
59.740.274,49€ or 65,90% of total expended finances in this group in 2010. Beta-
lactam antibacterial drugs with 11,71 DDD/1000 inh/day or 60,52%were drugs with
highest use in this subgroup, macrolides and lincosamides were at second place
with 3,23 DDD/1000 inh/day or 16,69%, while on the third place were quinolones
with 2,09 DDD/1000 inh/day or 10,80% of total drug utilization inside this subgroup.
Funding spent on beta-lactam antibacterial drugs was 36.469.664,56€ or 61,05%,
macrolides and lincosamides 8.573.022,83€ or 14,35%, and for quinolones
6.745.763,79€ or 11,29% of total funding spent for subgroup J01 in the year 2010.
CONCLUSIONS: In comparison to 2009 spending of group J in Serbia in 2010 year
was decreased for 18,35 DDD/1000 inh/day or 48,31%. The amount of funding spent
in this group, however, of drugs was decreased for only 20,03%.
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OBJECTIVES: To estimate the prevalence of potential interactions between anti-
platelet drugs, anticoagulants, digoxin and Chinese medications (CM) and further
to explore the determining factors associated with the occurrence of potential
interactions. METHODS: This study assessed the prevalence of exposure to the
major interactions between the seven selected western medications commonly
used for the cardiovascular diseases (i.e., aspirin, clopidogrel, digoxin, dipyridam-
ole, heparin, ticlopidine, and warfarin [in terms of high risk western medications,
HRWM]) and selected common used CM (i.e., American ginseng, Asian ginseng,
danshen, and dong quai), using the two-million National Health Insurance (NHI)
Research Database in Taiwan. Both univariate and multivariate logistic regression
analyses were conducted to identify the contributing factors (e.g., baseline demo-
graphics, comorbidities, health services utilizations) of potential major interac-
tions incidence. RESULTS: While 14.7% of HRWM users (19,431/131,804) ever used
those selected CM concurrently at anytime in 2007, 81.9% (15,919/19,431) of
HRWM-CM concurrent users had been exposed to at least one combination of
potentialmajor interactions. Anticoagulants (i.e., heparin andwarfarin) userswere
more likely to be prescribed with the selected CM with major interactions (86.7%
and 86%, respectively). The concomitant use of aspirinwith dong quai or Asian ginseng
wasmore prevalent than others. The factors that statistically significantly associated
with the incremental exposure of potential major interactions included female sex,
age 45-84 years old, higher number of outpatient visits, distinct medications pre-
scribed, and previous diagnosis of stroke. In contrast, those HRWM-CM users with
high monthly income, enrolled in the West region of Taiwan NHI, and had previous
history of acute respiratory infection were less likely to exposure to the major inter-
actions of HRWM-CM use. CONCLUSIONS: The exposure of the major interactions
with CMwas relative prevalent among HRWMusers in Taiwan. Further research is
needed to investigate the outcomes associated with such combinations.
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OBJECTIVES: Toexamine theprospective associationbetweenperceptionofhealthdur-
ing pregnancy and cardiovascular risk factor of mothers 21 years after the index
pregnancy.METHODS: Data used were from the Mater University Study of Pregnancy
(MUSP), a community- basedprospective birth cohort studybegun inBrisbane,Australia,
in 1983. Logistic regression analyses were conducted. RESULTS: Data were available for
3692 women.Womenwho perceived themselves as not having a straight forward preg-
nancy had twice the odds (adjusted OR 2.0, 95% CI 1.1-3.8) of being diagnosedwith heart
disease21yearsafter the indexpregnancyascomparedtowomenwithastraight forward
pregnancy. Apart from that, women who had complications (other than serious preg-
nancycomplications)during thepregnancywerealsoat30%increasedodds (adjustedOR
1.3, 95% CI 1.0-1.6) of having hypertension 21 years later. CONCLUSIONS: As a whole,
our study suggests that pregnant women who perceived that they had complica-
tions and did not have a straight forward pregnancy are likely to experience poorer
cardiovascular outcomes 21 years after the pregnancy.
CARDIOVASCULAR DISORDERS - Cost Studies
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OBJECTIVES: There were more than 200 million hypertension (HTN) patients in
China. Uncontrolled HTN results in strokes, myocardial infarction (MI) and other
complications, which are the leading cause of disability, death and severe eco-
nomic consequence.We conducted an economic evaluation to determine the costs
and quality-adjusted life years (QALYs) associated with Amlodipine (Norvasc) and
the Angiotensin II Receptor Blockers (ARBs) in preventing stroke and MI among
Chinese HTN patients.METHODS: A cost-utility analysis was conducted from the
third-party payer perspective. A Markov model was constructed to estimate five
year costs and health consequences (12-month cycles). For each arm, 10,000 pa-
tients were included for the simulation with Valsartan as comparator. Effective-
ness data on incidence of stroke and MI were based on a published meta-analysis.
Relative risks of stroke andMI were 0.84 and 0.83 respectively comparing Amlodip-
ine and ARBs. Utility data were retrieved from the published literature. Costs of MI
were retrieved fromChinese government reimbursement database. Costs of stroke
were obtained from retrospective chart review and follow-up interviews in Chinese
tertiary hospitals. Costs included costs of drugs, direct medical costs of hyperten-
sion management, stroke/MI treatment, and follow-up management. Discounting
rate used for costs and QALYs was 3%. RESULTS: Total direct medical and drug
costs of Amlodipine and Valsartan users are ¥111,731,716 and ¥132,058,611 respec-
tively; total QALYs of Amlodipine and Valsartan users are 30,648.5 and 30,520.8,
respectively. Amlodipine is dominant with lower costs and higher QALYs. This
demonstrated that, compared with Valsartan, Amlodipine is a cost saving therapy
with increased overall survival due to the reduction in stroke andMI events. When
Ibersartan data were used in the comparison, the magnitude of cost saving
changed but overall conclusion remained the same. CONCLUSIONS: Amolodipine
is a cost saving therapy compared with ARBs in preventing stroke and MI for Chi-
nese hypertension patients.
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OBJECTIVES: To examine a cohort of patients with all forms of cardiac arrhythmia
(CA) and identify factors associated with cost of care, health care resource utiliza-
tion, antiarrhythmic agent use, and quality of life. METHODS: This retrospective
database analysis utilized the household component data from 2004 to 2009
Agency for Healthcare Research and Quality Medical Panel Expenditure Survey.
Patients aged  18 and had any form of CA (identified via ICD-9-CM codes 427.0-
427.2, 427.31-427.32, 427.60-427.61, 427.69, 427.81, 427.89, 427.9, 785.0-785.1) were
included. Primary independent variables of interest included age, gender, race/
ethnicity, and pharmacotherapy use. Total annual health care expenditure, total
annual prescribed medicine expenditure, physical and mental component sum-
mary scores (PCS and MCS) of the Short-Form 12 version 2 (SF-12), EuroQoL-5D
(EQ-5D) utility scores (US version), proportion of patients using antiarrhythmic
medications, number of prescribed medications associated with their cardiac ar-
rhythmia, and proportion of patients with inpatient, outpatient, or emergency
room visits were the primary outcomes of interest. Multivariate ordinary least
squares (OLS) and generalized linear models (GLM) were used to analyze factors
related to the aforementioned outcomes. To provide national estimates, all results
were weighted and used standard errors (SE) calculated via Taylor-series
approaches. RESULTS: Annually, 5,750,440 non-institutionalized US persons were
estimated to suffer from cardiac arrhythmia between 2004 and 2009. Higher health
care expenditure and utilization appeared in non-Hispanic whites and patients
aged 65 (p0.05). As compared tomale patients, females had significantly higher
prescribed medication expenditure, lower proportion of inpatient and emergency
department visits related to arrhythmia, and lower PCS score (p0.05). Patients on
antiarrhythmics had significantly higher health care expenditures, lower propor-
tion of emergency department visits related to arrhythmia, and higher MCS score
(p0.05) compared with their counterparts. CONCLUSIONS: Potential health dis-
parities exist across age, gender, race, and antiarrhythmic use among CA patients.
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OBJECTIVES: Venous thromboembolism(VTE), a condition that includes deep vein
thrombosis(DVT) and pulmonary embolism(PE) is associated withmajormorbidity
andmortality and causes huge economic burden. The objective of this analysiswas
to determine the hospitalization costs and their predictors due to DVT/PE in China.
METHODS: A total of 278 patients with DVT or PE were randomly selected by
stratified two-stage sampling from the China BasicMedical Insurance Databases in
2009 and 2010. All information of patient demographic characters, length of stay,
clinical and costs were collected for the analysis. The descriptive statistics was
used to describe patients’ demographic characters, the hospital stay and the hos-
pital costs. Univariate and multivariable analyses were also used in the data
analysis. RESULTS: Total 278 patients (mean age 64.4 years; 58.3% male) were
evaluated, 61.9% of patients with DVT and 38.1% of patients with PE. The mean
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length-of-stay was 15.8 days (15.0 days for DVT patients and 17.0 days for PE pa-
tients). The mean total cost was Chinese Yuan (CNY) 16487.91 (median:9039.10,
IQR:5128.80-18981.83), CNY 17698.61 (median:8643.68, IQR:5025.03-19594.93) in pa-
tients with DVT and CNY 14523.39 (median:9879.25, IQR:5870.43 -ee18630.41) in
patients with PE. The average drug cost accounts for 47.4% of the total cost (mean:
6340.29; median:4479.94, IQR:2279.88-7991.12).The multiple linear regressions
showed that patients from tertiary hospitals had 105% higher costs than those
from primary hospitals (P  0.001), and patients from municipalities had 48.6%
higher costs than those from prefecture-level cities (P 0.01). CONCLUSIONS: The
costs per hospitalization associated with DVT or PE events are substantial. Hospi-
talization costs are now driven predominantly by the cost of drugs, levels of hos-
pitals and cities.
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OBJECTIVES: Acute coronary syndromes (ACS) consist mainly of ST-segment ele-
vation myocardial infarction (STEMI) and unstable angina (UA)/non-STEMI
(NSTEMI). ACS showed an enormous medical, social, and economic burden world-
wide. ACS in the form of myocardial infarction is responsible for almost half of all
deaths related to cardiovascular disease. South Korea compared to the OECD coun-
try average, shows high cardiovascular morbidity and mortality, and the recur-
rence rate is increasing every year. We examined the direct cost of hospitalization
for ACS which planned percutaneous coronary intervention (PCI) using medical
cost survey in South Korea.METHODS:We conducted a cost survey to examine the
actual direct medical costs of the team of cardiologists, technicians of intervention
and reimbursement reviewers in the hospital. To examine the cost data of a pa-
tients who received procedures, operations and admissions. We could select index
patient cases through medical chart review as he/she had ever been visited the
hospital since last 1 year. Through delphi panel discussion and reviewing, we
refined the cost data excluding non-related ACS treatment in index case. RESULTS:
It is the first survey of the actual cost in ACS. The totalmedical cost for ACS patients
who have undergone the procedure was 4.451 million Korean won. The cost is
lower level if considering difficulties in surgery. But among the components in ACS,
the cost of stents and devices were largely accounted for the total cost.
CONCLUSIONS: The medical cost of ACS in Korea is a burden to both patients and
society, due to increasing recurrence in cardiovascular disease. Among the total
cost, the cost of stents is higher than the inpatient cost. This is one of the reasons
of the highmedical cost in ACS. This result will have as implication the adjustment
of the cost of stents and devices in ACS treatment in South Korea.
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OBJECTIVES: Stroke is amajor cause of death around the world. This study aims to
evaluate the quality of care in pharmacist’s participation in a multidisciplinary
ischemic stroke team, and the potential cost avoidance associatedwith the recom-
mendations made by clinical pharmacists.METHODS:We conduct a retrospective
study at a stroke center with pharmacist participation in medical rounds. Six hun-
dred and forty-eight patients who suffered with stroke attack 10 days before ad-
mission are enrolled into sample. Data collects from November 2008 to September
2010. The patients with hemorrhage stroke are excluded from sample. Quality of
acute stroke care is assessed by five pharmaceutical care-related performance in-
dicators according to American Heart Association/American Stroke Association
Get With the Guidelines-Stroke program (GWTG-Stroke). The cost avoidance is
measured by the scored probability of harm. RESULTS: Study results show that
there is significantly improved in four performance indicators in the year of 2010
and 2008. Indicators with significant improvement include intravenous thrombo-
lytic (24.00% vs. 00.00%), early and discharge antithrombotic (95.93% vs. 93.33%,
96.56% vs. 93.18%), and anticoagulation for atrial fibrillation (71.43% vs. 20.00%).
The indicator of prescribing rate of lipid-lowing medications, however, remains
stable over two separate periods (51.70% versus 52.70%) due to the restriction of the
National Health Insurance Policy. The assumption that cost of prolonged length of
hospital stay due to ADE is about $5000 NTD. Therefore, cost avoidance was NT
$2,207,816 NTD in this study. CONCLUSIONS: This study demonstrates that phar-
macists involvement in a multidisciplinary ischemic stroke team are associated
with facilitating the quality of care and increasing potential cost avoidance.
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OBJECTIVES: To evaluate cost-effectiveness of adding ezetimibe to simvastatin
versus a switch to rosuvastatin or atorvastatin for high CHD risk patients who
cannot attain treatment goal (LDL-C  100 mg/dL) on their current simvastatin
dosage from Thai payer perspective.METHODS: A published Markov model (Cook
et al. 2004) was used to project lifetime costs and outcomes of lipid-lowering treat-
ment in primary and secondary CHD prevention. Lipid efficacy data were obtained
from clinical trials. Risks of CHD events and non CHD-related mortality rates were
estimated by using Framingham Heart Study risk equations and information from
Ministry of Public Health (MOPH), respectively. Disease-related costswere obtained
from published local studies. Drug prices were those published by MOPH. All costs
were expressed in THB 2010 values. Future costs and outcomes were discounted at
3%. Two scenarios were compared in the analysis: the addition of ezetimibe to
simvastatin 20 mg versus switching to rosuvastatin 10 mg and the addition of
ezetimibe to simvastatin 40 mg versus switching to atorvastatin 40 mg. RESULTS:
Ezetimibe co-administration increased life expectancy (LY) by 0.15 and 0.26 years
and resulted in 0.07 and 0.12 additional quality-adjusted life years (QALY) when
compared to a switch to rosuvastatin and a switch to atorvastatin, respectively.
The QALY gained would yield lifetime cost-savings of Baht 1,106 and 2,137 per
patient for such comparisons. Similar results were obtained where costs and out-
comes were either discounted or undiscounted. The sensitivity analyses showed
that results were robust to changes across scenarios. CONCLUSIONS: This analysis
suggested that addition of ezetimibe to simvastatin is the dominant treatment
strategy (more effective and less costly) in both scenarios. The results are very
imperative to assist policy decision-making in order to increase access to second-
line treatment option for patients not achieving lipid treatment goals with simva-
statin monotherapy in Thailand.
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OBJECTIVES: In response to TW-DRG implementation, based on safety, through
the radial artery cardiac catheterization intervention, how to make patients dis-
charged earlier, save health care costs and create a win-win between patients and
hospitals.METHODS: In this retrospective study in Han-Ming Hospital, Taiwan, we
enrolled 282 cases from January 1, 2006 to December 31, 2010. RESULTS: In the
admission less than 24 hours after the PCI treatment, there were 129 males and 51
females (64.312.5 years, mean s.d.). Besides, in other group over 24 hours, there
were 74 males and 28 females (69.111.5 years). Using Logistic Regression Analysis,
age65 years (RR 1.683, 95%CI 1.943-3.031, p-value 0.010,OR: 2.647,95%CI: 1.009-6.941,
p-value 0.030)eATroponin-I 1 ug/L(RR 1.963, 95%CI 1.254-15.155, p-value 0.001,OR:
2.053, 95%CI: 1.240-17.601, p-value 0.004)eAlesion numbers 2(RR 1.402, 95%CI 1.330-
5.955, p-value 0.001,OR:1.128, 95%CI: 1.120-10.617, p-value 0.008)eATreatments using
stents (RR 1.963, 95%CI 1.254-15.155, p-value 0.018,OR: 4.688, 95%CI:1.443-15.232, p-
value 0.033)eAvascular type such as A & B1 (RR 1.683, 95%CI 1.037-2.731, p-value
0.017,OR: 2.569, 95%CI: 1.751-8.794, p-value 0.036)eAnon-complication (RR 2.153,
95%CI 1.979-4.473, p-value 0.039,OR: 3.891, 95%CI: 1.011-25.801, p-value 0.043).
CONCLUSIONS: If patients have characteristics like age 65 years, Troponin-I 1
ug/L, lesion numbers less than 2, using stents, vascular type diagnosed as A and B1,
and non-complication, they could tend to discharge in 24 hours after PCI treat-
ment.
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OBJECTIVES: To conduct a pharmacoeconomic assessment of thrombolysis by in-
travenous recombinant tissue plasminogen activator (rt-PA) therapy for acute isch-
emic stroke (AIS) in a tertiary hospital in China.METHODS:A retrospective analysis
was conducted usingmedical records data among patients hospitalized for AIS and
receiving rt-PA therapy (time window: 6 hours after AIS) from September 2007 to
September 2008. A conservative therapy group (including antiplatelet, anticoagu-
lation, statin, traditional Chinesemedicine) werematched (1:1) on age, gender, risk
factors (hypertension, diabetes, previous stroke/TIA, high cholesterol/lipids and
coronary heart disease), Glasgow Coma Scale (GCS) and National Institutes of
Health Stroke Scale (NIHSS). Two groups were compared on 14th-day clinical out-
comes, utilities estimated from modified Rankin Scale (mRS) scores, and costs.
RESULTS: Forty patients (65%male, age 6511 years) in rt-PA and 40 patients (58%
male, age 6911 years) in conservative group were included. No differences were
found in mortality between 2 groups. Among survivors on 14th day, NIHSS
(meanSD: 1.892.64 vs. 4.385.57; P0.018 and mRS (0.771.26 vs. 1.921.80;
P0.002) were lower in rt-PA (N37) than conservative group (N39). Barth Index
(BI) was higher in rt-PA group (90.5716.71 vs. 74.3625.88; P0.002). Hospital
length-of-stay (LOS) was shorter in rt-PA (15.47.8 days) than conservative group
(19.28.80 days; P0.05). Total costs were not significantly different:
¥22,82611,049 (rt-PA) vs. ¥18,60510,713 (conservative), while total drug costs
were higher in rt-PA (¥13,3794,765) than conservative group (¥10,2256,222)
(P0.017). No difference was found in cost of hospital care (¥2,5742,608 vs.
¥2,2752,723), laboratory exam (¥1,8541,037 vs. ¥1,867974), etiology exam
(¥2,335823 vs. ¥2,1251,156) and traditional Chinese medicine (¥354266 vs.
¥278266) between rt-PA and conservative group. Utility gained with rt-PA was
0.04 (0.61 vs. 0.57). CONCLUSIONS: Intravenous rt-PA was associated with lower
patients’ disabilities, less hospital days, and comparable total costs compared to
conservative therapy for the management of AIS in this study population.
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LIFETIME COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS
WITH ACUTE CORONARY SYNDROMES BASED ON THE PLATO TRIAL: A
SINGAPORE HEALTH CARE PERSPECTIVE
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